[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alto Neuroscience Inc (ANRO)

Alto Neuroscience Inc (ANRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 753,606
  • Shares Outstanding, K 31,946
  • Annual Sales, $ 0 K
  • Annual Income, $ -63,240 K
  • EBIT $ -66 M
  • EBITDA $ -66 M
  • 60-Month Beta 1.62
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.70

Options Overview Details

View History
  • Implied Volatility 94.66% (-5.82%)
  • Historical Volatility 65.88%
  • IV Percentile 3%
  • IV Rank 2.41%
  • IV High 756.33% on 05/16/25
  • IV Low 78.34% on 04/21/26
  • Expected Move (DTE 34) 1.53 (6.62%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 43
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 1,334
  • Open Int (30-Day) 1,544
  • Expected Range 21.59 to 24.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.70
  • Number of Estimates 5
  • High Estimate $-0.54
  • Low Estimate $-0.99
  • Prior Year $-0.65
  • Growth Rate Est. (year over year) -7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.93 +5.99%
on 05/14/26
28.44 -18.27%
on 04/22/26
-2.23 (-8.74%)
since 04/15/26
3-Month
16.63 +39.77%
on 02/17/26
28.44 -18.27%
on 04/22/26
+6.35 (+37.62%)
since 02/13/26
52-Week
2.15 +981.12%
on 06/30/25
28.44 -18.27%
on 04/22/26
+20.81 (+856.54%)
since 05/15/25

Most Recent Stories

More News
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and...

ANRO : 23.00 (-2.50%)
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

– Phase 2b clinical trial of ALTO-207 in treatment-resistant depression (TRD) initiated – – New ALTO-101 analyses support significant effects on EEG markers of general...

ANRO : 23.00 (-2.50%)
Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...

ANRO : 23.00 (-2.50%)
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting

— Randomized, placebo-controlled, Phase 2a trial demonstrated robust, statistically significant antidepressant effects of ALTO-207 and favorable tolerability; supporting development of ALTO-207 in ~7...

ANRO : 23.00 (-2.50%)
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies — — Trial...

ANRO : 23.00 (-2.50%)
Stocks Recover on Hopes Strait of Hormuz Could Soon Reopen

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.11%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.11%. June E-mini...

ALK : 37.69 (-1.23%)
APO : 133.82 (-1.25%)
UAL : 93.80 (-2.31%)
ARES : 124.90 (-2.82%)
CARR : 65.32 (-2.11%)
$IUXX : 29,198.74 (-1.29%)
ZNM26 : 109-115 (-0.68%)
MTDR : 58.73 (+1.36%)
TSLA : 425.90 (-3.93%)
ESM26 : 7,460.75 (-0.86%)
NCLH : 15.69 (-1.51%)
BX : 118.81 (-2.98%)
Stocks Pare Losses on Hormuz Report

The S&P 500 Index ($SPX ) (SPY ) today is down -0.06%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.20%. June E-mini S&P futures...

ALK : 37.69 (-1.23%)
AMAT : 431.18 (-2.13%)
UAL : 93.80 (-2.31%)
MPC : 252.88 (+1.63%)
CVX : 188.86 (+1.19%)
$IUXX : 29,198.74 (-1.29%)
ASML : 1,511.31 (-4.62%)
ZNM26 : 109-115 (-0.68%)
OXY : 58.25 (+2.48%)
MTDR : 58.73 (+1.36%)
TSLA : 425.90 (-3.93%)
ESM26 : 7,460.75 (-0.86%)
Stocks Sink as President Trump Signals Iran War Will Drag On

The S&P 500 Index ($SPX ) (SPY ) today is down -1.13%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -1.15%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.53%. June E-mini S&P futures...

ALK : 37.69 (-1.23%)
APO : 133.82 (-1.25%)
GOOGL : 398.17 (-0.72%)
ARES : 124.90 (-2.82%)
AAPL : 299.06 (+0.29%)
SNDK : 1,387.24 (+0.33%)
HL : 18.02 (-7.35%)
CDE : 17.95 (-7.47%)
OXY : 58.25 (+2.48%)
TSLA : 425.90 (-3.93%)
FANG : 202.70 (+1.22%)
STX : 781.41 (-2.90%)
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements

— In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoint; signals observed across EEG measures including near-significant improvement in theta-ITC (p=0.052)...

ANRO : 23.00 (-2.50%)
Alto Neuroscience Announces $120 Million Private Placement Financing

– Financing led by Commodore Capital with participation from new and existing biotech focused investors – –  Alto expects to use the proceeds of the financing to...

ANRO : 23.00 (-2.50%)

Business Summary

Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company. Its clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia and other mental health conditions. Alto Neuroscience Inc. is based in LOS ALTOS, Calif.

See More

Key Turning Points

3rd Resistance Point 26.34
2nd Resistance Point 25.12
1st Resistance Point 24.36
Last Price 23.00
1st Support Level 22.38
2nd Support Level 21.16
3rd Support Level 20.40

See More

52-Week High 28.44
Last Price 23.00
Fibonacci 61.8% 18.40
Fibonacci 50% 15.30
Fibonacci 38.2% 12.19
52-Week Low 2.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.